The Vyvanse Files: A Whistleblower's Tale — Key Highlights
Detailed documentation and curated public records concerning The Vyvanse Files: A Whistleblower's Tale. Our editorial team continuously gathers verified updates, primary documentation, and multi-source context on this subject.
Comprehensive Findings & Archive
Sep 24, 2014 · the lawsuits were filed under the false claims act’s whistleblower provisions, which permit private parties to sue for false claims on behalf of the government and to share in.
Extract from the clinical evaluation report for lisdexamfetamine dimesilate proprietary product name:
Dec 15, 2014 · the lawsuits were filed under the false claims act’s whistleblower provisions, which permit private parties to sue for false claims on behalf of the government and to share in.
Nov 1, 2024 · soon after vyvanse’s patent expired in 2023, applications for generic formulations of lisdexamfetamine dimesylate started flowing into the fda.
Photographic Archive
